SB 256Session 2026
establishing safety and care requirements for clinician-administered drugs.
Progress
- Introduced
- In committee
- Passed Senate
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
Legislative history
-
House
Interim Study Report: Not Recommended for Future Legislation 10/15/2026 (Vote 11-0; )
-
House
Executive Session: 10/14/2026 10:00 am GP 229
-
House
Subcommittee Work Session: 10/07/2026 10:00 am GP 229
-
House
Subcommittee Work Session: 09/09/2026 10:00 am GP 229
-
House
Refer for Interim Study: MA VV 05/14/2026 HJ 13 P. 2
-
House
Committee Report: Refer for Interim Study 04/29/2026 (Vote 15-0; CC) HC 19 P. 6
-
House
Executive Session: 04/29/2026 10:00 am GP 229
-
House
Subcommittee Work Session: 04/22/2026 10:00 am GP 229
-
House
Public Hearing: 04/07/2026 02:15 pm GP 159
-
House
Subcommittee Work Session: 04/08/2026 10:00 am GP 229
-
House
Vacated and Referred to Commerce and Consumer Affairs (Rep. Kofalt): MA VV (in recess of) 02/19/2026 HJ 5 P. 127
-
House
Introduced (in recess of) 02/19/2026 and referred to Health, Human Services and Elderly Affairs HJ 5 P. 124
-
Senate
Ought to Pass with Amendment #2025-3029s, MA, VV; OT3rdg; 01/07/2026; SJ 1
-
Senate
Committee Amendment # 2025-3029s, AA, VV; 01/07/2026; SJ 1
-
Senate
Committee Report: Ought to Pass with Amendment # 2025-3029s, 01/07/2026; Vote 5-0; CC; SC 46
-
Senate
Rereferred to Committee, MA, VV; 03/06/2025; SJ 6
-
Senate
Committee Report: Rereferred to Committee, 03/06/2025; Vote 5-0; CC; SC 11
-
Senate
Hearing: 02/12/2025, Room 101, LOB, 09:15 am; SC 9
-
Senate
Introduced 01/09/2025 and Referred to Health and Human Services; SJ 3